Magnetic resonance imaging of iron metabolism with T2* mapping predicts an enhanced clinical response to pharmacological ascorbate in patients with GBM.

Michael S Petronek Varun V Monga Kellie L Bodeker Michael Kwofie Chu-Yu Lee Kranti A Mapuskar Jeffrey M Stolwijk Amira Zaher Brett A Wagner Mark C Smith Sandy Vollstedt Heather Brown Meghan L Chandler Amanda C Lorack Jared S Wulfekuhle Jann N Sarkaria Ryan T Flynn Jeremy D W Greenlee Matthew A Howard Brian J Smith Karra A Jones Garry R Buettner Joseph J Cullen Joel J St-Aubin John M Buatti Vincent A Magnotta Douglas R Spitz Bryan G Allen

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

P-AscH- combined with temozolomide and radiotherapy has the potential to significantly enhance GBM survival. T2*-based MRI assessment of tumor iron content is a prognostic biomarker for GBM clinical outcomes.

Keyphrases

magnetic resonance imaging
contrast enhanced
iron deficiency
early stage
computed tomography
high resolution
diffusion weighted imaging
radiation therapy
locally advanced
newly diagnosed
magnetic resonance
climate change
clinical evaluation